title: Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir.
abstract: Herpes simplex virus-2 (HSV-2) suppression with acyclovir or valacyclovir reduces HIV-1 viral RNA levels; one hypothesis is that HSV-2 suppression reduces immune activation. We measured T cell immune activation markers among women participating in a randomized placebo-controlled trial of valacyclovir to reduce HIV-1 RNA levels among pregnant women. Although valacyclovir was associated with lower HIV-1 RNA levels, the distribution of both CD4(+) and CD8(+) CD38(+)HLA-DR(+) T cells was not different among women taking valacyclovir when compared to women taking placebo. Further study is needed to understand the mechanism of HIV-1 RNA reduction following herpes suppression among those coinfected with HIV-1 and HSV-2.
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA 98104, USA. aroxby@u.washington.edu
authors.forename: Alison C
authors.initials: AC
authors.lastname: Roxby
authors.forename: Amy Y
authors.initials: AY
authors.lastname: Liu
authors.forename: Alison L
authors.initials: AL
authors.lastname: Drake
authors.forename: James N
authors.initials: JN
authors.lastname: Kiarie
authors.forename: Barbra
authors.initials: B
authors.lastname: Richardson
authors.forename: Barbara L
authors.initials: BL
authors.lastname: Lohman-Payne
authors.forename: Grace C
authors.initials: GC
authors.lastname: John-Stewart
authors.forename: Anna
authors.initials: A
authors.lastname: Wald
authors.forename: Stephen
authors.initials: S
authors.lastname: De Rosa
authors.forename: Carey
authors.initials: C
authors.lastname: Farquhar
mesh_terms: D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D060085:Coinfection / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D004311:Double-Blind Method; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology; D006561:Herpes Simplex / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D018258:Herpesvirus 2, Human / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007630:Kenya; D008213:Lymphocyte Activation / Q000276:immunology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D018139:Simplexvirus / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir